September 20, 2016 09:30 AM EDT
R&D

Pri­do­pi­dine is still a mess in lat­est Hunt­ing­ton’s study, but Te­va maps PhI­II

John Carroll

Editor & Founder

Six years ago a Dan­ish com­pa­ny called Neu­roSearch en­joyed a few days in the sun when it said its ex­per­i­men­tal drug for Hunt­ing­ton’s diease, Huntex­il …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times